Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The most important causative factor for anaphylaxis in mastocytosis are insect stings. The purpose of this review is to analyse the available data concerning prevalence, diagnosis, safety and effectiveness of venom immunotherapy (VIT) in mastocytosis patients. If data were unclear, authors were contacted personally for further information. Quality of evidence (A: high, B: moderate, C: low and D: very low) and strength of recommendation (strong 1 and weak 2) concerning VIT in mastocytosis patients are assessed according to the Grading of Recommendations Assessment, Development and Evaluation and are marked in square brackets. Results of VIT were described in 117 patients to date. The mean rate of side‐effects during treatment in studies published so far is 23.9% (7.6% requiring adrenaline) with an overall protection rate of 72%. Based on the review we conclude that (1) mastocytosis patients have a high risk of severe sting reactions in particular to yellow jacket, (2) VIT could be suggested [2] in mastocytosis, (3) probably should be done life long [2], (4) VIT in mastocytosis is accompanied by a higher frequency of side‐effects, so (5) special precautions should be taken into account notably during the built up phase of the therapy [2], (6) VIT is able to reduce systemic reactions, but to a lesser extent compared to the general insect venom allergic population [2], so (7) patients should be warned that the efficacy of VIT might be less than optimal and they should continue carrying two adrenaline auto injectors [2].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Going from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Brożek, J. L., Akl, E. A., Alonso‐Coello, P., Lang, D., Jaeschke, R., Williams, J. W., Phillips, B., Lelgemann, M., Lethaby, A., Bousquet, J., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.01973.x · Cited by 894
Allergy Diagnostic Testing: An Updated Practice Parameter
Bernstein, I. L., Li, J. T., Bernstein, D. I., Hamilton, R., Spector, S. L., Tan, R., Sicherer, S., Golden, D. B. K., Khan, D. A., Nicklas, R. A., et al. (2008) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)60305-5 · Cited by 723
Bonadonna, P., Perbellini, O., Passalacqua, G., Caruso, B., Colarossi, S., Dal Fior, D., Castellani, L., Bonetto, C., Frattini, F., Dama, A., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.11.018 · Cited by 392
Understanding the mechanisms of anaphylaxis
Peavy, R. D., & Metcalfe, D. D. (2008) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0b013e3283036a90 · Cited by 211
Oude Elberink, J. N. G., de Monchy, J. G. R., Kors, J. W., van Doormaal, J. J., & Dubois, A. E. J. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)81058-5 · Cited by 203
Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis
Carter, M. C., Robyn, J. A., Bressler, P. B., Walker, J. C., Shapiro, G. G., & Metcalfe, D. D. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.03.032 · Cited by 172
Cited by
Stinging insect hypersensitivity
Golden, D. B. K., Demain, J., Freeman, T., Graft, D., Tankersley, M., Tracy, J., Blessing-Moore, J., Bernstein, D., Dinakar, C., Greenhawt, M., et al. (2017) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2016.10.031 · Cited by 267
Valent, P., Bonadonna, P., Hartmann, K., Broesby-Olsen, S., Brockow, K., Butterfield, J. H., Triggiani, M., Lyons, J. J., Oude Elberink, J. N. G., Arock, M., et al. (2019) · International Archives of Allergy and Immunology · doi:10.1159/000501079 · Cited by 146
Self-citationThe mastocytosis society survey on mast cell disorders: patient experiences and perceptions
Jennings, S., Russell, N., Jennings, B., Slee, V., Sterling, L., Castells, M., Valent, P., & Akin, C. (2014) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2013.09.004 · Cited by 143
“In addition to food and drug reactions, reports indicate 20% to 30% of patients with mastocytosis experience insect venom-induced anaphylaxis.(16,24) The TMS survey used the term anaphylactic shock along with a severity scale, which, although medically incorrect, may have been interpreted by patients as “anaphylaxis.”
BackgroundÁlvarez-Twose, I., Zanotti, R., González-de-Olano, D., Bonadonna, P., Vega, A., Matito, A., Sánchez-Muñoz, L., Morgado, J. M., Perbellini, O., García-Montero, A., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.06.020 · Cited by 142
Mast cell activation syndromes: definition and classification
Valent, P. (2013) · Allergy · doi:10.1111/all.12126 · Cited by 120
Metadata
- Authors
- Niedoszytko, M., De Monchy, J., Van Doormaal, J. J., Jassem, E., & Oude Elberink, J. N. G.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2009-09
- Volume
- 64
- Issue
- 9
- Pages
- 1237-1245
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W1982411214
- Cited by
- 157
- References
- 7
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. https://app.cochat.ai/papers/10.1111/j.1398-9995.2009.02118.x
- The paper
- Niedoszytko, M., De Monchy, J., Van Doormaal, J. J., Jassem, E., & Oude Elberink, J. N. G. (2009). Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy. https://doi.org/10.1111/j.1398-9995.2009.02118.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.